These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35791694)

  • 1. Inducing Hypermutability to Promote Anti-PD-1 Therapy Response.
    Willis JA; Overman MJ
    Cancer Discov; 2022 Jul; 12(7):1612-1614. PubMed ID: 35791694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients.
    Crisafulli G; Sartore-Bianchi A; Lazzari L; Pietrantonio F; Amatu A; Macagno M; Barault L; Cassingena A; Bartolini A; Luraghi P; Mauri G; Battuello P; Personeni N; Zampino MG; Pessei V; Vitiello PP; Tosi F; Idotta L; Morano F; Valtorta E; Bonoldi E; Germano G; Di Nicolantonio F; Marsoni S; Siena S; Bardelli A
    Cancer Discov; 2022 Jul; 12(7):1656-1675. PubMed ID: 35522273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors.
    Llosa NJ; Luber B; Tam AJ; Smith KN; Siegel N; Awan AH; Fan H; Oke T; Zhang J; Domingue J; Engle EL; Roberts CA; Bartlett BR; Aulakh LK; Thompson ED; Taube JM; Durham JN; Sears CL; Le DT; Diaz LA; Pardoll DM; Wang H; Anders RA; Housseau F
    Clin Cancer Res; 2019 Sep; 25(17):5250-5259. PubMed ID: 31061070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.
    Amodio V; Lamba S; Chilà R; Cattaneo CM; Mussolin B; Corti G; Rospo G; Berrino E; Tripodo C; Pisati F; Bartolini A; Aquilano MC; Marsoni S; Mauri G; Marchiò C; Abrignani S; Di Nicolantonio F; Germano G; Bardelli A
    Cancer Cell; 2023 Jan; 41(1):196-209.e5. PubMed ID: 36584674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
    Le DT; Uram JN; Wang H; Bartlett BR; Kemberling H; Eyring AD; Skora AD; Luber BS; Azad NS; Laheru D; Biedrzycki B; Donehower RC; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Duffy SM; Goldberg RM; de la Chapelle A; Koshiji M; Bhaijee F; Huebner T; Hruban RH; Wood LD; Cuka N; Pardoll DM; Papadopoulos N; Kinzler KW; Zhou S; Cornish TC; Taube JM; Anders RA; Eshleman JR; Vogelstein B; Diaz LA
    N Engl J Med; 2015 Jun; 372(26):2509-20. PubMed ID: 26028255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer.
    Pietrantonio F; Randon G; Romagnoli D; Di Donato S; Benelli M; de Braud F
    Cancer Treat Rev; 2020 Jan; 82():101935. PubMed ID: 31821983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial.
    Haag GM; Springfeld C; Grün B; Apostolidis L; Zschäbitz S; Dietrich M; Berger AK; Weber TF; Zoernig I; Schaaf M; Waberer L; Müller DW; Al-Batran SE; Halama N; Jaeger D
    Eur J Cancer; 2022 May; 167():112-122. PubMed ID: 35427833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TiME to Respond.
    Willis JA; Overman MJ; Vilar E
    Clin Cancer Res; 2019 Sep; 25(17):5185-5187. PubMed ID: 31263028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA).
    Almuhaisen G; Alhalaseh Y; Mansour R; Abu-Shanab A; Al-Ghnimat S; Al-Hussaini M
    Brain Tumor Pathol; 2021 Jan; 38(1):14-22. PubMed ID: 32897465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in immunotherapy for MMR proficient colorectal cancer.
    Lote H; Starling N; Pihlak R; Gerlinger M
    Cancer Treat Rev; 2022 Dec; 111():102480. PubMed ID: 36335756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Colorectal Cancer.
    Mukherji R; Weinberg BA; Pedersen KS
    Hematol Oncol Clin North Am; 2022 Jun; 36(3):603-626. PubMed ID: 35577706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status.
    Ahtiainen M; Wirta EV; Kuopio T; Seppälä T; Rantala J; Mecklin JP; Böhm J
    Mod Pathol; 2019 Jun; 32(6):866-883. PubMed ID: 30723299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mismatch repair deficient metastatic colon cancer and urothelial cancer: A case report of sequential immune checkpoint therapy.
    Ghatalia P; Nagarathinam R; Cooper H; Geynisman DM; El-Deiry WS
    Cancer Biol Ther; 2017 Sep; 18(9):651-654. PubMed ID: 28726535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
    He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL
    Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer.
    Yarchoan M; Huang CY; Zhu Q; Ferguson AK; Durham JN; Anders RA; Thompson ED; Rozich NS; Thomas DL; Nauroth JM; Rodriguez C; Osipov A; De Jesus-Acosta A; Le DT; Murphy AG; Laheru D; Donehower RC; Jaffee EM; Zheng L; Azad NS
    Cancer Med; 2020 Feb; 9(4):1485-1494. PubMed ID: 31876399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
    Konstantinopoulos PA; Luo W; Liu JF; Gulhan DC; Krasner C; Ishizuka JJ; Gockley AA; Buss M; Growdon WB; Crowe H; Campos S; Lindeman NI; Hill S; Stover E; Schumer S; Wright AA; Curtis J; Quinn R; Whalen C; Gray KP; Penson RT; Cannistra SA; Fleming GF; Matulonis UA
    J Clin Oncol; 2019 Oct; 37(30):2786-2794. PubMed ID: 31461377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade.
    Wang T; Lee LH; Vyas M; Zhang L; Ganesh K; Firat C; Segal NH; Desai A; Hechtman JF; Ntiamoah P; Weiser MR; Markowitz AJ; Vakiani E; Klimstra DS; Stadler ZK; Shia J
    Mod Pathol; 2019 Oct; 32(10):1551-1562. PubMed ID: 31175329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.
    Burren S; Reche K; Blank A; Galvàn JA; Dawson H; Berger MD; Zlobec I; Lugli A
    Pathol Res Pract; 2021 Jul; 223():153486. PubMed ID: 34051513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A further investigation of combined mismatch repair and BRAFV600E mutation specific immunohistochemistry as a predictor of overall survival in colorectal carcinoma.
    Luey N; Toon CW; Sioson L; Clarkson A; Watson N; Cussigh C; Kedziora A; Pincott S; Pillinger S; Evans J; Percy J; Engel A; Schnitzler M; Gill AJ
    PLoS One; 2014; 9(8):e106105. PubMed ID: 25153715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.